Cochrane · systematic review · CD014678
Non‐vitamin‐K‐antagonist oral anticoagulants (NOACs) after acute myocardial infarction: a network meta‐analysis
Al Said, S, Kaier, K, Sumaya, W, et al. · Cochrane Database of Systematic Reviews · 2024 · Cochrane Library
HeartAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
9
current version
GRADE rated
9
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 3 · 33.3%Moderate 3 · 33.3%High 3 · 33.3%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Non‐vitamin‐K‐antagonist oral anticoagulants versus placebo in adults with acute myocardial infarction and without an indication for anticoagulation: all‐cause mortality
Population: adults after AMI without an indication for anticoagulation
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Apixaban (all doses combined) vs placebo Non‐vitamin‐K‐antagonist oral anticoagulants vs placebo | no estimate extracted | 2 studies · 8638 participants | Moderate Downgraded: imprecision |
Rivaroxaban (all doses combined) vs placebo Non‐vitamin‐K‐antagonist oral anticoagulants vs placebo | no estimate extracted | 3 studies · 21870 participants | High |
Dabigatran (all doses combined) vs placebo Non‐vitamin‐K‐antagonist oral anticoagulants vs placebo | no estimate extracted | 1 study · 1861 participants | Low Downgraded: imprecision |
Non‐vitamin‐K‐antagonist oral anticoagulants versus placebo in adults with acute myocardial infarction and without an indication for anticoagulation: cardiovascular mortality
Population: adults after AMI without an indication for anticoagulation
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Apixaban (all doses combined) vs placebo Non‐vitamin‐K‐antagonist oral anticoagulants vs placebo | no estimate extracted | 2 studies · 8638 participants | Moderate Downgraded: imprecision |
Rivaroxaban (all doses combined) vs placebo Non‐vitamin‐K‐antagonist oral anticoagulants vs placebo | no estimate extracted | 3 studies · 21870 participants | Moderate Downgraded: imprecision |
Dabigatran (all doses combined) vs placebo Non‐vitamin‐K‐antagonist oral anticoagulants vs placebo | no estimate extracted | 1 study · 1861 participants | Low Downgraded: imprecision |
Non‐vitamin‐K‐antagonist oral anticoagulants versus placebo in adults with acute myocardial infarction and without an indication for anticoagulation: major bleeding
Population: adults after AMI without an indication for anticoagulation
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Apixaban (all doses combined) vs placebo Non‐vitamin‐K‐antagonist oral anticoagulants vs placebo | no estimate extracted | 2 studies · 8544 participants | High |
Rivaroxaban (all doses combined) vs placebo Non‐vitamin‐K‐antagonist oral anticoagulants vs placebo | no estimate extracted | 3 studies · 21870 participants | High |
Dabigatran (all doses combined) vs placebo Non‐vitamin‐K‐antagonist oral anticoagulants vs placebo | no estimate extracted | 1 study · 1861 participants | Low Downgraded: imprecision |